Cargando…

COVID19 vaccine in myasthenia gravis patients: safety and possible predictors of disease exacerbation

Detalles Bibliográficos
Autores principales:	Trinchillo, Assunta, Esposito, Marcello, Habetswallner, Francesco, Tuccillo, Francesco, De Martino, Bernardo Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790762/ https://www.ncbi.nlm.nih.gov/pubmed/36567408 http://dx.doi.org/10.1007/s10072-022-06584-w

Ejemplares similares

COVID-19 vaccination in myasthenia gravis: safe, but predictors of disease exacerbation yet to be determined
por: Kim, Sohyeon, et al.
Publicado: (2023)

An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis
por: Wang, H.Y., et al.
Publicado: (2023)

Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023)

Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review
por: Rodrigues, Cleonisio Leite, et al.
Publicado: (2022)

Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic
por: Ricciardi, Dario, et al.
Publicado: (2021)

Respiratory dysfunction as first presentation of myasthenia gravis misdiagnosed as COVID-19
por: Scopelliti, Giuseppe, et al.
Publicado: (2020)

Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
por: Mimori, Masahiro, et al.
Publicado: (2022)

The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis
por: Galassi, Giuliana
Publicado: (2022)

New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series
por: Fanella, Gaia, et al.
Publicado: (2022)

Letter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”
por: Nóbrega, Paulo Ribeiro, et al.
Publicado: (2022)

Reply to Letter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”
por: Galassi, Giuliana, et al.
Publicado: (2022)

A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment
por: Alis, Ceren, et al.
Publicado: (2022)

The impact of the reclusion on patients with blepharospasm during the COVID19 pandemic
por: Trinchillo, Assunta, et al.
Publicado: (2022)

Isolated COVID-19 Infection Precipitates Myasthenia Gravis Crisis: A Case Report
por: Moschella, Phillip, et al.
Publicado: (2020)

The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis
por: Seok, Hung Youl, et al.
Publicado: (2017)

Parental concerns about COVID-19 vaccine safety and hesitancy in Korea: implications for vaccine communication
por: Cho, Hye-Kyung, et al.
Publicado: (2022)

Predictors of COVID-19 booster vaccine hesitancy among fully vaccinated adults in Korea: a nationwide cross-sectional survey
por: Noh, Yunha, et al.
Publicado: (2022)

Heart inflammation risk after COVID-19 vaccine
por: Szarpak, Lukasz, et al.
Publicado: (2021)

Maternal COVID-19, vaccination safety in pregnancy, and evidence of protective immunity
por: Pham, Amelie, et al.
Publicado: (2021)

Safety of COVID-19 vaccine in patients with epilepsy: a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2022)

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
por: Kim, Sohyeon, et al.
Publicado: (2023)

Bilateral anterior ischemic optic neuropathy after COVID-vaccination
por: Iodice, Francesco, et al.
Publicado: (2023)

Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy
por: Antonini, Giovanni, et al.
Publicado: (2023)

The vulnerability to COVID-19 of migrants in large urban areas: structural exacerbators and community-level mitigators
por: Hitch, Lisa, et al.
Publicado: (2023)

Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
por: Syversen, Silje W., et al.
Publicado: (2022)

Clinical predictors for the prognosis of myasthenia gravis
por: Wang, Lili, et al.
Publicado: (2017)

Oral Mucosal Lesions Possibly Associated with COVID-19
Publicado: (2022)

Post COVID‐19 vaccination: AusVaxSafety survey participation and adverse events – a community‐based regional Queensland study
por: Hamilton, Elizabeth, et al.
Publicado: (2022)

Facemask headache: a new nosographic entity among healthcare providers in COVID-19 era
por: Rapisarda, Laura, et al.
Publicado: (2021)

COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
por: Tanzilli, Antonio, et al.
Publicado: (2022)

Predictors of survival in older adults hospitalized with COVID-19
por: Tyson, Brad, et al.
Publicado: (2021)

A Possible Scenario for the Covid-19 Epidemic, Based on the SI(R) Model
por: Rocchi, Ettore, et al.
Publicado: (2020)

Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
por: Dror, Amiel A., et al.
Publicado: (2021)

Myositis associated to COVID-19 mimics an acute exacerbation in myasthenia gravis patient
por: De Martino, Antonio, et al.
Publicado: (2021)

Worldwide Recommendations and Therapies for Multiple Sclerosis: Are They Safe in the COVID-19 Pandemic Period?
por: Ferrara, Francesco, et al.
Publicado: (2020)

The Central Role of Clinical Nutrition in COVID-19 Patients During and After Hospitalization in Intensive Care Unit
por: Ferrara, Francesco, et al.
Publicado: (2020)

COVID-19 impact on neurology training program in Italy
por: Di Lorenzo, Francesco, et al.
Publicado: (2021)

Predictors of In-Hospital Mortality in Older Patients With COVID-19: The COVIDAge Study
por: Mendes, Aline, et al.
Publicado: (2020)

Predictors of “brain fog” 1 year after COVID-19 disease
por: Cristillo, Viviana, et al.
Publicado: (2022)

Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis
por: Díez-Porras, Laura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u05tgbtnk5829jiuaifcd5424o